Diabetes
Conditions
Keywords
Diabetes, Acute MI, Ang II type-1 receptor blockade (AT1RB), LV remodeling, ACE inhibitor therapy, XO inhibitor, Allopurinol, Systolic dysfunction, Diastolic dysfunction, LV dimensions, Cardiac MRI
Brief summary
The investigators hypothesize that in patients with diabetes and acute myocardial infarction (MI), Ang II type-1 receptor blockade (AT1RB) attenuates left ventricle (LV) remodeling to a greater extent than angiotensin converting enzyme (ACE) inhibitor therapy and that the addition of xanthine oxidase (XO) inhibitor, Allopurinol, results in further improvement in LV remodeling and function in the follow-up phase after MI.
Detailed description
Following myocardial infarction (MI), the incidence of heart failure and mortality rates are approximately two-fold higher in patients with diabetes compared to those without diabetes. This increased risk for heart failure and mortality appears to be refractory to currently available treatments such as angiotensin converting enzyme (ACE) inhibitors, despite the effectiveness of such treatments in reducing overall morbidity and mortality following MI. Hyperglycemia stimulates cardiomyocyte angiotensin II (Ang II) formation, which has been implicated in increased myocyte cell death in diabetes. Furthermore, in humans, chymase is the predominant pathway of Ang II formation and this pathway of Ang II production is not blocked by ACE inhibition. Therefore, in diabetes where Ang II levels may already be elevated due to hyperglycemia the increase in Ang II formation associated with left ventricular (LV) remodeling continued Ang II formation from chymase could be particularly detrimental. In addition to enhanced Ang II production, hyperglycemia and diabetes also amplify the production of reactive oxygen species (ROS). ROS are associated with increased in LV remodeling and myocyte apoptosis. Furthermore, xanthine oxidase (XO), an important source of ROS in myocytes, is increased in a rat model of myocardial infarction and in diabetes. Thus, increased XO-mediated ROS production following MI may be especially damaging in diabetic patients where ROS production is already elevated. Interestingly, acute treatment with Allopurinol, an inhibitor of XO, improves cardiac function in heart failure and improves endothelial dysfunction in patients with type-2 diabetes. To test our hypothesis the investigators will investigate the following aims in diabetic patients after acute MI: Aim 1: Show that the progression of LV remodeling and dysfunction in diabetic patients will be attenuated to greater extent by AT1RB than by ACE inhibitor. Aim 2: Show that the addition of XO inhibition results in further attenuation of LV remodeling than with AT1RB or ACE inhibitor alone. Aim 3: Show that baseline and follow-up LV remodeling and dysfunction and inflammatory markers differ in diabetic and non-diabetic patients post-MI.
Interventions
DRUGRamipril
The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
DRUGCandesartan cilexetil
The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
DRUGAllopurinol
The starting dose of Allopurinol is 300 mg daily.
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
AstraZeneca
University of Alabama at Birmingham
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 21 years old or older 2. MI documented by increase in troponin \> 0.78 ng/ml or CKMB ≥ 3% of total CK Patients who have Type-2 diabetes defined by any one of the following: 3. Confirmed (i.e., two or more readings) fasting blood glucose \>126mg/dl; or 4. Random glucose ≥200mg/dl; or 5. 2 hour glucose ≥200mg/dl following 75g of glucose; or 6. Current treatment with diet or oral agents directed at the control of hyperglycemia either alone or in combination with insulin; or 7. Current treatment with insulin with no prior history of diabetic ketoacidosis.
Exclusion criteria
1. Type-1 diabetes. 2. Class III or IV heart failure. 3. Cardiomyopathy (including hypertrophic and amyloidosis). 4. Congenital or pericardial diseases. 5. Intolerance to either ACE inhibitor, AT1-RB or allopurinol. 6. Renal failure with creatinine \> 2.5 mg/dl. 7. Renal artery stenosis. 8. Severe comorbidity such as liver disease or malignancy. 9. Pregnancy (negative pregnancy test and effective contraceptive methods are required prior to enrollment of females of childbearing potential (not post-menopausal or surgically sterilized). 10. Chronic steroid use. 11. Unable to understand or cooperate with protocol requirements. 12. Severe claustrophobia. 13. Presence of a pacemaker or non-removable hearing aid. 14. Presence of metal clips in the body.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | 5 visits per Participant over 2 years (about every 6 months) | LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. |
| Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | 5 visits per Participant over 2 years (about every 6 months) | LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. |
| Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | 5 visits per Participant over 2 years (about every 6 months) | LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. |
| Left Ventricular Ejection Fraction (LVEF) | 5 visits per Participant over 2 years (about every 6 months) | LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes |
| Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | 5 visits per Participant over 2 years (about every 6 months) | LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. |
| LV End Systolic Maximum Shortening (LVES Max Shortening) | 5 visits per Participant over 2 years (about every 6 months) | By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. |
| Peak Early Filling Rate Normalized to EDV | 5 visits per Participant over 2 years (about every 6 months) | The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ramipril The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. | 18 |
| Candesartan Cilexetil The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. | 18 |
| Ramipril and Allopurinol The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. It is anticipated that the starting dose of each drug will be initiated in hospital and that the second dose will be implemented prior to discharge from the hospital. The starting dose of Allopurinol is 300 mg daily. | 18 |
| Candesartan Cilexetil and Allopurinol The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. The starting dose of Allopurinol is 300 mg daily. | 18 |
| Total | 72 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Death | 0 | 0 | 1 | 1 |
| Overall Study | decline in health | 0 | 0 | 1 | 0 |
| Overall Study | patient refuses follow-up | 5 | 4 | 2 | 4 |
| Overall Study | Physician Decision | 0 | 1 | 0 | 0 |
| Overall Study | placed in long-term care | 0 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 2 | 3 | 2 |
Baseline characteristics
| Characteristic | Candesartan Cilexetil | Ramipril and Allopurinol | Ramipril | Candesartan Cilexetil and Allopurinol | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 6 Participants | 7 Participants | 6 Participants | 8 Participants | 27 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants | 11 Participants | 12 Participants | 10 Participants | 45 Participants |
| Age Continuous | 60.94 years STANDARD_DEVIATION 11.27 | 60.67 years STANDARD_DEVIATION 10.57 | 58.17 years STANDARD_DEVIATION 10.61 | 62 years STANDARD_DEVIATION 10.86 | 60.44 years STANDARD_DEVIATION 10.69 |
| Region of Enrollment United States | 18 participants | 18 participants | 18 participants | 18 participants | 72 participants |
| Sex: Female, Male Female | 3 Participants | 8 Participants | 2 Participants | 3 Participants | 16 Participants |
| Sex: Female, Male Male | 15 Participants | 10 Participants | 16 Participants | 15 Participants | 56 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 3 / 18 | 4 / 18 | 6 / 18 | 3 / 18 |
| serious Total, serious adverse events | 4 / 18 | 6 / 18 | 9 / 18 | 5 / 18 |
Outcome results
Primary
Left Ventricular Ejection Fraction (LVEF)
LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes
Time frame: 5 visits per Participant over 2 years (about every 6 months)
Population: intent to treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 0 (n=17,17,18,18) | 52.19 percent | Standard Deviation 10.65 |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 24 (n=11,9,8,10) | 57.18 percent | Standard Deviation 9.79 |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 12(n=12,11,11,11) | 52.76 percent | Standard Deviation 9.94 |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 6(n=14,11,11,12) | 54.20 percent | Standard Deviation 10.27 |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 21(n=3,0,0,1) | 51.27 percent | Standard Deviation 1.73 |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 9(n=1,2,0,0) | 64.98 percent | — |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 27 (n=1,1,0,1) | 50.73 percent | — |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 18(n=10,12,8,8) | 55.02 percent | Standard Deviation 13.24 |
| Ramipril | Left Ventricular Ejection Fraction (LVEF) | Month 15(n=3,2,1,1) | 52.13 percent | Standard Deviation 14.08 |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 6(n=14,11,11,12) | 56.82 percent | Standard Deviation 10.81 |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 21(n=3,0,0,1) | NA percent | — |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 24 (n=11,9,8,10) | 51.70 percent | Standard Deviation 10.02 |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 27 (n=1,1,0,1) | 54.17 percent | — |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 0 (n=17,17,18,18) | 56.36 percent | Standard Deviation 12.34 |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 18(n=10,12,8,8) | 56.33 percent | Standard Deviation 10.26 |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 9(n=1,2,0,0) | 42.62 percent | Standard Deviation 1.95 |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 12(n=12,11,11,11) | 52.37 percent | Standard Deviation 11.41 |
| Candesartan Cilexetil | Left Ventricular Ejection Fraction (LVEF) | Month 15(n=3,2,1,1) | 39.88 percent | Standard Deviation 2.76 |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 24 (n=11,9,8,10) | 55.59 percent | Standard Deviation 9.47 |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 21(n=3,0,0,1) | NA percent | — |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 15(n=3,2,1,1) | 34.89 percent | — |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 12(n=12,11,11,11) | 51.74 percent | Standard Deviation 15.54 |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 27 (n=1,1,0,1) | NA percent | — |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 0 (n=17,17,18,18) | 53.37 percent | Standard Deviation 10.01 |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 18(n=10,12,8,8) | 54.05 percent | Standard Deviation 9.96 |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 6(n=14,11,11,12) | 52.80 percent | Standard Deviation 15.66 |
| Ramipril and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 9(n=1,2,0,0) | NA percent | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 27 (n=1,1,0,1) | 54.40 percent | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 15(n=3,2,1,1) | 54.46 percent | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 21(n=3,0,0,1) | 56.17 percent | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 24 (n=11,9,8,10) | 55.79 percent | Standard Deviation 10.53 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 0 (n=17,17,18,18) | 52.68 percent | Standard Deviation 13.9 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 6(n=14,11,11,12) | 57.28 percent | Standard Deviation 9.17 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 9(n=1,2,0,0) | NA percent | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 12(n=12,11,11,11) | 56.11 percent | Standard Deviation 11.33 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular Ejection Fraction (LVEF) | Month 18(n=10,12,8,8) | 57.82 percent | Standard Deviation 10.97 |
Primary
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV)
LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes.
Time frame: 5 visits per Participant over 2 years (about every 6 months)
Population: intent to treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 15(n=3,2,1,1) | 0.81 g/ml | Standard Deviation 0.16 |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 21(n=3,0,0,1) | 0.95 g/ml | Standard Deviation 0.25 |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 18(n=10,12,8,8) | 0.79 g/ml | Standard Deviation 0.16 |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 0 (n=17,17,18,18) | 0.92 g/ml | Standard Deviation 0.25 |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 9(n=1,2,0,0) | 0.75 g/ml | — |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 6(n=14,11,11,12) | 0.87 g/ml | Standard Deviation 0.18 |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 27 (n=1,1,0,1) | 0.93 g/ml | — |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 24 (n=11,9,8,10) | 0.84 g/ml | Standard Deviation 0.18 |
| Ramipril | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 12(n=12,11,11,11) | 0.84 g/ml | Standard Deviation 0.18 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 21(n=3,0,0,1) | NA g/ml | — |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 15(n=3,2,1,1) | 0.70 g/ml | Standard Deviation 0.18 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 24 (n=11,9,8,10) | 0.80 g/ml | Standard Deviation 0.2 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 6(n=14,11,11,12) | 0.83 g/ml | Standard Deviation 0.13 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 12(n=12,11,11,11) | 0.78 g/ml | Standard Deviation 0.19 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 9(n=1,2,0,0) | 0.67 g/ml | Standard Deviation 0.11 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 0 (n=17,17,18,18) | 0.95 g/ml | Standard Deviation 0.27 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 18(n=10,12,8,8) | 0.79 g/ml | Standard Deviation 0.22 |
| Candesartan Cilexetil | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 27 (n=1,1,0,1) | 0.64 g/ml | — |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 6(n=14,11,11,12) | 0.71 g/ml | Standard Deviation 0.17 |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 0 (n=17,17,18,18) | 0.86 g/ml | Standard Deviation 0.26 |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 9(n=1,2,0,0) | NA g/ml | — |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 12(n=12,11,11,11) | 0.72 g/ml | Standard Deviation 0.15 |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 15(n=3,2,1,1) | 0.57 g/ml | — |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 18(n=10,12,8,8) | 0.83 g/ml | Standard Deviation 0.16 |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 21(n=3,0,0,1) | NA g/ml | — |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 24 (n=11,9,8,10) | 0.80 g/ml | Standard Deviation 0.14 |
| Ramipril and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 27 (n=1,1,0,1) | NA g/ml | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 0 (n=17,17,18,18) | 0.87 g/ml | Standard Deviation 0.13 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 21(n=3,0,0,1) | 0.69 g/ml | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 9(n=1,2,0,0) | NA g/ml | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 27 (n=1,1,0,1) | 0.69 g/ml | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 24 (n=11,9,8,10) | 0.82 g/ml | Standard Deviation 0.08 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 6(n=14,11,11,12) | 0.82 g/ml | Standard Deviation 0.12 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 18(n=10,12,8,8) | 0.80 g/ml | Standard Deviation 0.12 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 15(n=3,2,1,1) | 0.68 g/ml | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV) | Month 12(n=12,11,11,11) | 0.86 g/ml | Standard Deviation 0.13 |
Primary
Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness)
LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes.
Time frame: 5 visits per Participant over 2 years (about every 6 months)
Population: intent to treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 12(n=12,11,11,11) | 3.43 unitless | Standard Deviation 0.71 |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 21(n=3,0,0,1) | 2.92 unitless | Standard Deviation 0.43 |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 15(n=3,2,1,1) | 3.44 unitless | Standard Deviation 0.56 |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 18(n=10,12,8,8) | 3.60 unitless | Standard Deviation 0.69 |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 24 (n=11,9,8,10) | 3.46 unitless | Standard Deviation 0.74 |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 0 (n=17,17,18,18) | 3.23 unitless | Standard Deviation 0.77 |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 27 (n=1,1,0,1) | 3.12 unitless | — |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 6(n=14,11,11,12) | 3.32 unitless | Standard Deviation 0.7 |
| Ramipril | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 9(n=1,2,0,0) | 3.42 unitless | — |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 12(n=12,11,11,11) | 3.68 unitless | Standard Deviation 0.68 |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 15(n=3,2,1,1) | 4.10 unitless | Standard Deviation 1.1 |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 0 (n=17,17,18,18) | 3.14 unitless | Standard Deviation 0.79 |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 9(n=1,2,0,0) | 4.14 unitless | Standard Deviation 0.84 |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 18(n=10,12,8,8) | 3.71 unitless | Standard Deviation 0.76 |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 21(n=3,0,0,1) | NA unitless | — |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 24 (n=11,9,8,10) | 3.58 unitless | Standard Deviation 0.69 |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 27 (n=1,1,0,1) | 4.04 unitless | — |
| Candesartan Cilexetil | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 6(n=14,11,11,12) | 3.39 unitless | Standard Deviation 0.44 |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 27 (n=1,1,0,1) | NA unitless | — |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 6(n=14,11,11,12) | 4.04 unitless | Standard Deviation 0.75 |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 0 (n=17,17,18,18) | 3.57 unitless | Standard Deviation 0.98 |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 9(n=1,2,0,0) | NA unitless | — |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 12(n=12,11,11,11) | 4.01 unitless | Standard Deviation 0.71 |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 15(n=3,2,1,1) | 4.57 unitless | — |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 18(n=10,12,8,8) | 3.60 unitless | Standard Deviation 0.55 |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 21(n=3,0,0,1) | NA unitless | — |
| Ramipril and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 24 (n=11,9,8,10) | 3.61 unitless | Standard Deviation 0.57 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 12(n=12,11,11,11) | 3.42 unitless | Standard Deviation 0.47 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 9(n=1,2,0,0) | NA unitless | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 6(n=14,11,11,12) | 3.63 unitless | Standard Deviation 0.61 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 21(n=3,0,0,1) | 4.24 unitless | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 27 (n=1,1,0,1) | 4.29 unitless | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 0 (n=17,17,18,18) | 3.45 unitless | Standard Deviation 0.61 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 15(n=3,2,1,1) | 3.90 unitless | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 24 (n=11,9,8,10) | 3.56 unitless | Standard Deviation 0.37 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness) | Month 18(n=10,12,8,8) | 3.56 unitless | Standard Deviation 0.48 |
Primary
Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA)
LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals.
Time frame: 5 visits per Participant over 2 years (about every 6 months)
Population: intent to treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 6(n=14,11,11,12) | 74.10 ml/m^2 | Standard Deviation 15.53 |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 27 (n=1,1,0,1) | 48.68 ml/m^2 | — |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 18(n=10,12,8,8) | 75.28 ml/m^2 | Standard Deviation 14.48 |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 9(n=1,2,0,0) | 73.23 ml/m^2 | — |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 15(n=3,2,1,1) | 81.19 ml/m^2 | Standard Deviation 5.96 |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month12(n=12,11,11,11) | 75.34 ml/m^2 | Standard Deviation 20.3 |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 0 (n=17,17,18,18) | 73.03 ml/m^2 | Standard Deviation 20.34 |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 24 (n=11,9,8,10) | 70.46 ml/m^2 | Standard Deviation 17.17 |
| Ramipril | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 21(n=3,0,0,1) | 71.99 ml/m^2 | Standard Deviation 28.13 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 9(n=1,2,0,0) | 93.57 ml/m^2 | Standard Deviation 18.48 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 24 (n=11,9,8,10) | 84.28 ml/m^2 | Standard Deviation 23.17 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 27 (n=1,1,0,1) | 76.65 ml/m^2 | — |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 0 (n=17,17,18,18) | 78.06 ml/m^2 | Standard Deviation 18.4 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 6(n=14,11,11,12) | 78.60 ml/m^2 | Standard Deviation 24.3 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month12(n=12,11,11,11) | 85.44 ml/m^2 | Standard Deviation 20.87 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 15(n=3,2,1,1) | 90.20 ml/m^2 | Standard Deviation 13.24 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 18(n=10,12,8,8) | 82.74 ml/m^2 | Standard Deviation 23.09 |
| Candesartan Cilexetil | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 21(n=3,0,0,1) | NA ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 6(n=14,11,11,12) | 86.13 ml/m^2 | Standard Deviation 24.14 |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 9(n=1,2,0,0) | NA ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 21(n=3,0,0,1) | NA ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month12(n=12,11,11,11) | 83.95 ml/m^2 | Standard Deviation 20.69 |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 15(n=3,2,1,1) | 108.25 ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 24 (n=11,9,8,10) | 71.63 ml/m^2 | Standard Deviation 8.59 |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 27 (n=1,1,0,1) | NA ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 18(n=10,12,8,8) | 67.96 ml/m^2 | Standard Deviation 12.86 |
| Ramipril and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 0 (n=17,17,18,18) | 78.52 ml/m^2 | Standard Deviation 19.31 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 18(n=10,12,8,8) | 84.95 ml/m^2 | Standard Deviation 17.55 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 6(n=14,11,11,12) | 78.01 ml/m^2 | Standard Deviation 14.49 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 9(n=1,2,0,0) | NA ml/m^2 | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 21(n=3,0,0,1) | 75.27 ml/m^2 | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 0 (n=17,17,18,18) | 79.03 ml/m^2 | Standard Deviation 21.39 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 24 (n=11,9,8,10) | 79.72 ml/m^2 | Standard Deviation 15.11 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month12(n=12,11,11,11) | 79.75 ml/m^2 | Standard Deviation 19.9 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 15(n=3,2,1,1) | 63.1 ml/m^2 | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) | Month 27 (n=1,1,0,1) | 75.05 ml/m^2 | — |
Primary
Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA)
LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals.
Time frame: 5 visits per Participant over 2 years (about every 6 months)
Population: intent to treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 21(n=3,0,0,1) | 35.23 ml/m^2 | Standard Deviation 14.52 |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 0 (n=17,17,18,18) | 36.20 ml/m^2 | Standard Deviation 16.64 |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 6(n=14,11,11,12) | 34.77 ml/m^2 | Standard Deviation 13.56 |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 9(n=1,2,0,0) | 25.64 ml/m^2 | — |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 12(n=12,11,11,11) | 36.82 ml/m^2 | Standard Deviation 15.88 |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 15(n=3,2,1,1) | 39.42 ml/m^2 | Standard Deviation 14.05 |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 18(n=10,12,8,8) | 35.30 ml/m^2 | Standard Deviation 17.21 |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 24 (n=11,9,8,10) | 31.17 ml/m^2 | Standard Deviation 14.47 |
| Ramipril | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 27 (n=1,1,0,1) | 23.98 ml/m^2 | — |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 21(n=3,0,0,1) | NA ml/m^2 | — |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 15(n=3,2,1,1) | 54.04 ml/m^2 | Standard Deviation 5.47 |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 6(n=14,11,11,12) | 35.26 ml/m^2 | Standard Deviation 18.36 |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 18(n=10,12,8,8) | 37.76 ml/m^2 | Standard Deviation 18.48 |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 27 (n=1,1,0,1) | 35.13 ml/m^2 | — |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 0 (n=17,17,18,18) | 35.26 ml/m^2 | Standard Deviation 16.08 |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 12(n=12,11,11,11) | 42.27 ml/m^2 | Standard Deviation 19.83 |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 9(n=1,2,0,0) | 53.87 ml/m^2 | Standard Deviation 12.43 |
| Candesartan Cilexetil | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 24 (n=11,9,8,10) | 41.72 ml/m^2 | Standard Deviation 18.48 |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 6(n=14,11,11,12) | 42.88 ml/m^2 | Standard Deviation 25.33 |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 24 (n=11,9,8,10) | 31.56 ml/m^2 | Standard Deviation 6.52 |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 9(n=1,2,0,0) | NA ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 12(n=12,11,11,11) | 42.34 ml/m^2 | Standard Deviation 25.18 |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 15(n=3,2,1,1) | 70.48 ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 18(n=10,12,8,8) | 30.39 ml/m^2 | Standard Deviation 4.61 |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 21(n=3,0,0,1) | NA ml/m^2 | — |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 0 (n=17,17,18,18) | 37.91 ml/m^2 | Standard Deviation 16.63 |
| Ramipril and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 27 (n=1,1,0,1) | NA ml/m^2 | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 6(n=14,11,11,12) | 34.15 ml/m^2 | Standard Deviation 12.8 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 12(n=12,11,11,11) | 36.07 ml/m^2 | Standard Deviation 16.24 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 21(n=3,0,0,1) | 32.99 ml/m^2 | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 24 (n=11,9,8,10) | 35.99 ml/m^2 | Standard Deviation 13.65 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 9(n=1,2,0,0) | NA ml/m^2 | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 15(n=3,2,1,1) | 28.74 ml/m^2 | — |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 0 (n=17,17,18,18) | 39.49 ml/m^2 | Standard Deviation 21.97 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 18(n=10,12,8,8) | 37.18 ml/m^2 | Standard Deviation 15.95 |
| Candesartan Cilexetil and Allopurinol | Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA) | Month 27 (n=1,1,0,1) | 34.22 ml/m^2 | — |
Primary
LV End Systolic Maximum Shortening (LVES Max Shortening)
By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes.
Time frame: 5 visits per Participant over 2 years (about every 6 months)
Population: intent to treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 21(n=3,0,0,1) | 16.68 percent of length at end of filling | Standard Deviation 1.27 |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 9(n=1,2,0,0) | 18.43 percent of length at end of filling | — |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 27 (n=1,1,0,1) | 13.70 percent of length at end of filling | — |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 6(n=14,11,10,12) | 16.88 percent of length at end of filling | Standard Deviation 1.9 |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 24 (n=11,9,8,10) | 15.67 percent of length at end of filling | Standard Deviation 3.36 |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 12(n=11,11,10,10) | 14.57 percent of length at end of filling | Standard Deviation 2.91 |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 18(n=10,12,7,8) | 17.26 percent of length at end of filling | Standard Deviation 1.46 |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 0 (n=17,17,17,18) | 15.81 percent of length at end of filling | Standard Deviation 3.56 |
| Ramipril | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 15(n=3,2,1,1) | 17.06 percent of length at end of filling | Standard Deviation 1.83 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 21(n=3,0,0,1) | NA percent of length at end of filling | — |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 15(n=3,2,1,1) | 16.28 percent of length at end of filling | Standard Deviation 2.42 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 18(n=10,12,7,8) | 17.55 percent of length at end of filling | Standard Deviation 1.62 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 6(n=14,11,10,12) | 17.50 percent of length at end of filling | Standard Deviation 2.07 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 24 (n=11,9,8,10) | 16.62 percent of length at end of filling | Standard Deviation 1.32 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 9(n=1,2,0,0) | 19.08 percent of length at end of filling | Standard Deviation 2.78 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 0 (n=17,17,17,18) | 16.68 percent of length at end of filling | Standard Deviation 3.12 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 12(n=11,11,10,10) | 17.13 percent of length at end of filling | Standard Deviation 1.94 |
| Candesartan Cilexetil | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 27 (n=1,1,0,1) | 20.38 percent of length at end of filling | — |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 15(n=3,2,1,1) | 14.22 percent of length at end of filling | — |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 0 (n=17,17,17,18) | 15.84 percent of length at end of filling | Standard Deviation 2.7 |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 6(n=14,11,10,12) | 18.72 percent of length at end of filling | Standard Deviation 2.4 |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 9(n=1,2,0,0) | NA percent of length at end of filling | — |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 12(n=11,11,10,10) | 17.96 percent of length at end of filling | Standard Deviation 1.68 |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 18(n=10,12,7,8) | 17.46 percent of length at end of filling | Standard Deviation 1.19 |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 21(n=3,0,0,1) | NA percent of length at end of filling | — |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 24 (n=11,9,8,10) | 17.52 percent of length at end of filling | Standard Deviation 1.17 |
| Ramipril and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 27 (n=1,1,0,1) | NA percent of length at end of filling | — |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 24 (n=11,9,8,10) | 17.85 percent of length at end of filling | Standard Deviation 1.37 |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 21(n=3,0,0,1) | 17.89 percent of length at end of filling | — |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 9(n=1,2,0,0) | NA percent of length at end of filling | — |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 6(n=14,11,10,12) | 18.50 percent of length at end of filling | Standard Deviation 2 |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 27 (n=1,1,0,1) | 16.59 percent of length at end of filling | — |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 0 (n=17,17,17,18) | 16.00 percent of length at end of filling | Standard Deviation 2.77 |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 18(n=10,12,7,8) | 17.52 percent of length at end of filling | Standard Deviation 1.6 |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 15(n=3,2,1,1) | 16.36 percent of length at end of filling | — |
| Candesartan Cilexetil and Allopurinol | LV End Systolic Maximum Shortening (LVES Max Shortening) | Month 12(n=11,11,10,10) | 18.51 percent of length at end of filling | Standard Deviation 2.41 |
Primary
Peak Early Filling Rate Normalized to EDV
The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes.
Time frame: 5 visits per Participant over 2 years (about every 6 months)
Population: intent to treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 0 (n=17,17,18,18) | 1.93 1/sec | Standard Deviation 0.69 |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 18(n=10,12,8,8) | 1.91 1/sec | Standard Deviation 0.52 |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 9(n=1,2,0,0) | 2.50 1/sec | — |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 27 (n=1,1,0,1) | 1.34 1/sec | — |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 6(n=14,11,11,12) | 1.74 1/sec | Standard Deviation 0.77 |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 24 (n=11,9,8,10) | 2.05 1/sec | Standard Deviation 0.81 |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 21(n=3,0,0,1) | 1.69 1/sec | Standard Deviation 0.42 |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 15(n=3,2,1,1) | 2.02 1/sec | Standard Deviation 1.09 |
| Ramipril | Peak Early Filling Rate Normalized to EDV | Month 12(n=12,11,11,11) | 1.80 1/sec | Standard Deviation 0.6 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 18(n=10,12,8,8) | 1.93 1/sec | Standard Deviation 0.84 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 21(n=3,0,0,1) | NA 1/sec | — |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 24 (n=11,9,8,10) | 1.65 1/sec | Standard Deviation 0.55 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 0 (n=17,17,18,18) | 2.01 1/sec | Standard Deviation 0.76 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 15(n=3,2,1,1) | 1.48 1/sec | Standard Deviation 0.58 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 6(n=14,11,11,12) | 2.02 1/sec | Standard Deviation 0.81 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 9(n=1,2,0,0) | 1.13 1/sec | Standard Deviation 0.83 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 12(n=12,11,11,11) | 1.90 1/sec | Standard Deviation 0.71 |
| Candesartan Cilexetil | Peak Early Filling Rate Normalized to EDV | Month 27 (n=1,1,0,1) | 1.10 1/sec | — |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 27 (n=1,1,0,1) | NA 1/sec | — |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 9(n=1,2,0,0) | NA 1/sec | — |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 21(n=3,0,0,1) | NA 1/sec | — |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 12(n=12,11,11,11) | 1.93 1/sec | Standard Deviation 0.45 |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 24 (n=11,9,8,10) | 1.88 1/sec | Standard Deviation 0.5 |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 15(n=3,2,1,1) | 1.56 1/sec | — |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 6(n=14,11,11,12) | 2.03 1/sec | Standard Deviation 0.95 |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 18(n=10,12,8,8) | 1.89 1/sec | Standard Deviation 0.78 |
| Ramipril and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 0 (n=17,17,18,18) | 2.11 1/sec | Standard Deviation 0.56 |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 24 (n=11,9,8,10) | 1.82 1/sec | Standard Deviation 0.78 |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 12(n=12,11,11,11) | 1.77 1/sec | Standard Deviation 0.83 |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 27 (n=1,1,0,1) | 2.15 1/sec | — |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 0 (n=17,17,18,18) | 2.0 1/sec | Standard Deviation 0.74 |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 6(n=14,11,11,12) | 1.98 1/sec | Standard Deviation 0.73 |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 15(n=3,2,1,1) | 2.28 1/sec | — |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 18(n=10,12,8,8) | 2.05 1/sec | Standard Deviation 0.59 |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 21(n=3,0,0,1) | 2.50 1/sec | — |
| Candesartan Cilexetil and Allopurinol | Peak Early Filling Rate Normalized to EDV | Month 9(n=1,2,0,0) | NA 1/sec | — |